Cardiomed S.R.L.

At Cardiomed S.R.L. in Cluj Napoca, much of the clinical research focuses on lung cancer and other solid tumors. Studies are exploring new treatment combinations, comparing them with current standards, and measuring outcomes such as survival, tumor response, and disease control.

• Advanced and metastatic non-small cell lung cancer, including biomarker-defined subgroups
• Small-cell lung cancer and resectable lung cancer in the perioperative setting
• Testing immunotherapy-based combinations and targeted therapies against established treatments
• Evaluating whether new approaches can improve overall survival, progression-free survival, and response rates

These trials reflect a strong interest in improving care for patients with advanced thoracic cancers, especially where treatment options are limited or where personalized therapy may offer added benefit.

Research at this site also includes cancers of the esophagus, stomach, and colon. The studies are designed to assess whether newer drug combinations can improve tumor control and extend survival compared with standard therapy.

• Esophageal carcinoma and gastroesophageal adenocarcinoma
• Metastatic colorectal cancer with specific molecular features
• Comparing combination therapy approaches with current standard regimens
• Seeking better outcomes in advanced digestive tract cancers

This area of research highlights the site’s role in evaluating treatment effectiveness for difficult-to-treat gastrointestinal malignancies.

The site is contributing to research in cardiovascular disease, with studies aimed at lowering the risk of major heart and vascular events. The main focus is prevention in people at elevated risk for atherosclerotic cardiovascular disease.

• Primary prevention of atherosclerotic cardiovascular disease
• Reducing the chance of heart attack, stroke, and related complications
• Evaluating whether a new therapy can improve prevention beyond placebo or usual care

These trials are centered on long-term risk reduction and improving protection against serious cardiovascular events.

Another important research area is chronic rhinosinusitis with nasal polyps, where trials are assessing treatments intended to ease symptoms and reduce polyp burden. The goal is to improve day-to-day breathing comfort and overall disease control.

• Chronic rhinosinusitis with nasal polyps (CRSwNP)
• Measuring improvement in nasal congestion and polyp severity
• Exploring patient experience and treatment satisfaction alongside clinical outcomes

This work combines symptom-focused research with patient-reported perspectives, helping to better understand how treatment affects quality of life.

The oncology portfolio at Cardiomed S.R.L. includes several studies focused on tumors defined by specific biomarkers or genetic alterations. These trials are testing whether targeted therapies and immunotherapy combinations can improve outcomes in selected patient groups.

• HER2-positive and KRAS G12C-mutated cancers
• Renal cell carcinoma, bladder cancer, and head and neck squamous cell carcinoma
• Assessing whether personalized treatment strategies can outperform standard options
• Focusing on survival, recurrence prevention, and anti-tumor activity

Overall, the site is active in precision oncology research, with trials aimed at matching treatment to tumor biology and improving outcomes across several advanced cancer types.